DDInter1936 DDInter1676
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Vinblastine {u} (Compound) resembles {v} (Compound) Vindesine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinblastine {u} (Compound) treats {v} (Disease) kidney cancer
Vinblastine {u} (Compound) binds {v} (Gene) TUBB3
Vinblastine {u} (Compound) upregulates {v} (Gene) OSBPL2
Vinblastine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinblastine {u} (Compound) downregulates {v} (Gene) TMEM168
Vinblastine {u} (Compound) causes {v} (Side Effect) Paraesthesia
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Vinblastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluorouracil
Vinblastine (Compound) resembles Vindesine (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Vinblastine (Compound) treats kidney cancer (Disease)
Vinblastine (Compound) binds TUBB3 (Gene)
Vinblastine (Compound) upregulates OSBPL2 (Gene)
Vinblastine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinblastine (Compound) downregulates TMEM168 (Gene)
Vinblastine (Compound) causes Paraesthesia (Side Effect)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil